
April 3 (Reuters) - Intellia Therapeutics Inc NTLA.O:
INTELLIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE MAGNITUDE-2 PHASE 3 STUDY OF NEXIGURAN ZICLUMERAN (NEX-Z), A ONE-TIME GENE EDITING-BASED TREATMENT FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY
INTELLIA THERAPEUTICS INC: PLANS TO SUBMIT A BIOLOGICS LICENSING APPLICATION FOR ATTRV-PN BY 2028